Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488) announced that China’s National Medical Products Administration (NMPA) has granted approval to initiate clinical trials for ADC119, a Category 2.3 anti-HIV fixed-dose combination product. ADC119 represents China’s first domestically developed complete HIV treatment regimen, combining Aidea’s novel Category 1 NNRTI ainovirin (ANV) with established nucleoside reverse transcriptase inhibitors (NRTIs) emtricitabine (FTC) and tenofovir alafenamide (TAF) for treatment-naïve adult patients with HIV-1 infection.

Regulatory Milestone & Product Profile

Therapeutic Innovation & Clinical Rationale

Component Breakdown

• Ainovirin (ANV): First domestic Category 1 oral anti-HIV new drug in China; non-nucleoside reverse transcriptase inhibitor (NNRTI)
• Emtricitabine (FTC): Well-established NRTI with proven efficacy and safety profile
• Tenofovir Alafenamide (TAF): Next-generation NRTI with improved renal and bone safety compared to tenofovir disoproxil fumarate (TDF)

Strategic Advantages

• Complete Regimen: Single-tablet solution eliminating need for multiple prescriptions
• Domestic Innovation: Reduces China’s dependence on imported HIV therapeutics
• Optimized Safety: TAF component provides enhanced safety profile over older tenofovir formulations
• Treatment Simplification: Once-daily dosing improves patient adherence and treatment outcomes

Market Context & Strategic Significance

China HIV Treatment Landscape

• Patient Population: Estimated 1.2 million people living with HIV in China as of 2026
• Treatment Gap: Significant portion still relies on imported antiretroviral therapies
• Policy Support: National emphasis on domestic pharmaceutical innovation for critical disease areas

Competitive Positioning

• First-Mover Advantage: Only domestic complete HIV regimen in Chinese development pipeline
• Cost Accessibility: Potential for significantly lower pricing compared to imported triple-combination therapies
• Supply Chain Security: Domestic manufacturing reduces import dependency and supply chain risks

Development Strategy & Commercial Implications

Clinical Development Pathway

• Phase 1/2 Trials: Initial safety, pharmacokinetics, and dose-finding studies
• Phase 3 Pivotal Trial: Head-to-head comparison with standard-of-care regimens
• Regulatory Strategy: Leveraging Category 2.3 classification for expedited review pathways

Commercial Outlook

• Market Access: Strong potential for inclusion in national HIV treatment guidelines
• Reimbursement: High likelihood of National Reimbursement Drug List (NRDL) inclusion given public health importance
• Revenue Potential: Estimated peak annual sales of ¥800 million-¥1.5 billion ($110-210 million) in Chinese market alone

Strategic Impact for Jiangsu Aidea

This clinical trial approval marks a transformative milestone for Jiangsu Aidea, establishing the company as China’s leader in domestic HIV therapeutic development. The successful integration of their proprietary ANV molecule with established NRTIs demonstrates sophisticated combination therapy expertise and positions Aidea to capture significant market share in China’s growing HIV treatment market.

The ADC119 program also validates Aidea’s broader antiviral platform, potentially enabling future expansion into other viral indications and combination regimens leveraging their NNRTI expertise.

Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, clinical development timelines, and market opportunities. Actual results may differ materially due to clinical trial outcomes, regulatory requirements, competitive dynamics, and other risk factors inherent in pharmaceutical development.-Fineline Info & Tech